FDA Decides on Lonvo-z Gene Therapy by March 2027

Intellia Therapeutics' hereditary angioedema treatment would be the first in vivo gene-editing therapy correcting genes directly inside the body if approved.

Updated on Nov. 16, 2026 in Biotech

Isometric editorial illustration of smooth spherical particles clustered in a cross-section of a liver cell, with a twisted helical bundle nested among them.
The U.S. Food and Drug Administration will decide by March 2027 whether to approve Intellia Therapeutics' lonvo-z, a single-infusion CRISPR therapy for hereditary angioedema. AI Illustration. Upload story photo >

Live Poll

Would you trust a one-time gene-editing treatment for a serious inherited disease?

The U.S. Food and Drug Administration will decide by March 2027 whether to approve lonvo-z, a hereditary angioedema treatment developed by Intellia Therapeutics. Lonvo-z is given as a single intravenous infusion that silences the gene responsible for the swelling-causing substance produced in the liver.

Why it matters

If approved, lonvo-z would be the first therapy to use CRISPR gene-editing technology to directly correct genes inside the body. The decision would mark a step beyond Casgevy, the first approved CRISPR therapy, which treats sickle cell anemia.

A phase 3 trial with 80 participants found lonvo-z patients experienced 87% fewer swelling attacks than placebo patients, with 62% needing no additional preventive treatment. Earlier phase 1/2 follow-ups showed effects lasting years after a single dose, but the FDA's final decision remains pending until March 2027.

The players

Intellia Therapeutics

Intellia Therapeutics is a U.S. biotechnology company developing gene-editing therapies, including lonvo-z for hereditary angioedema.

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency responsible for reviewing and approving drugs and biologics sold in the United States.

The details

Lonvo-z encapsulates CRISPR gene-editing components, a guide RNA that locates faulty DNA and a Cas9 protein that cuts the target site, in lipid nanoparticles. These particles travel through the bloodstream and enter liver cells to silence the gene that produces the swelling-causing substance.

Timeline

  1. 2012: CRISPR gene-editing technology was introduced.

  2. 2020: Jennifer Doudna and Emmanuelle Charpentier received the Nobel Prize in Chemistry for CRISPR work.

  3. 2023: Casgevy was approved to treat sickle cell anemia.

  4. March 2027: FDA decision deadline on lonvo-z.

The Big Picture

Casgevy, approved in 2023 to treat sickle cell anemia, was the first CRISPR gene-editing therapy on the market, but it edits cells outside the body. Lonvo-z would advance the field by delivering gene editing directly into the liver through a single intravenous infusion.

If approved, lonvo-z would be given as a single infusion rather than requiring ongoing preventive medication for hereditary angioedema patients. The therapy's lasting effects after one dose could reduce the frequency of treatments for people living with this rare disorder.

The takeaway

Gene-editing therapies are moving from treating blood cells in a lab to correcting genes inside the body itself. Lonvo-z's upcoming FDA decision will show whether that approach can reach regulatory approval.

What happens next

The FDA is scheduled to decide on lonvo-z approval by March 2027, and Verve Therapeutics plans phase 2 trials for VERVE-102.

Further reading

Explore more Biotech developments shaping gene-editing therapies across the United States.

Live Poll

Would you trust a one-time gene-editing treatment for a serious inherited disease?